NCT07469137Active, not recruiting
THE RELATIONSHIP BETWEEN CARDIAC RESYNCHRONİZATION THERAPY RESPONSE IN HEART FAILURE PATIENTS AND YKL-40 LEVELS
RELATIONSHIP BETWEEN YKL-40 LEVELS IN CORONARY SINUS AND PERIPHERAL BLOOD DURING CARDIAC RESYNCHRONIZATION THERAPY (CRT) PROCEDURE AND CRT RESPONSE IN FOLLOW-UPS
Source: ClinicalTrials.gov · Last updated 13 Mar 2026
Brief summary (registry, in English)
Patients diagnosed with heart failure at our clinic who routinely undergo CRT implantation will be included in the study. This decision is independent of the study. In patients included in the study, after routine placement of a coronary sinus catheter, 2 cc of blood will be drawn from this catheter without performing any additional invasive procedures on the patient. Additionally, one peripheral blood sample will be collected from the patient's routinely accessed antebrachial vein. The blood samples will be centrifuged at 4000 rpm (revolutions per minute) for 10 minutes to separate the serum and stored at -80 °C until analyzed. The demographic, clinical, laboratory, electrocardiographic, and echocardiographic data of these patients will be recorded. At the 6-month follow-up clinic visit after discharge, routine heart failure parameters, routine echocardiographic data, and routine ECG recordings will be obtained. The procedures to be performed after discharge are routine for patients who have undergone CRT implantation at our clinic, and no additional follow-up or tests will be performed for this study. After all data are recorded, statistical evaluation will be performed. Data will be reviewed through the ENLİL HBYS system. The best criteria for determining CRT response have not been clearly established. Many studies have been conducted to predict CRT response in advance. A review of the literature shows that YKL-40 levels in the blood are associated with cardiovascular diseases, but no study in the literature has shown the relationship between YKL-40 levels and CRT implantation in patients.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 51 (actual)
- First submitted
- 9 Mar 2026
- Start date
- 1 Mar 2025
- Primary completion date
- 1 Jun 2026
- Lead sponsor
- Trakya University
- Diseases
- Heart failure
- NCT number
- NCT07469137
What you commit to
- Study type: Observational
- Participants enrolled: 51
- From 1 Mar 2025 to the primary completion date, 1 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients not receiving optimal medical treatment
Other illness
- Malignancy patients with an expected survival period of less than 1 year
- Patients with chronic inflammatory and rheumatological diseases
Age
- Patients under the age of 18
Other
- Those who declined to participate in the study
Who the study is looking for
- Patients diagnosed with heart failure, with an EF ≤35, who remain in heart failure stages 2-3-4 despite optimal medical therapy, and who have LBBB and a QRS duration of at least 130 msec.
- Those who agreed to participate in the study
- Patients diagnosed with heart failure and who have been monitored, and for whom a permanent pacemaker has been decided due to the presence of a high-degree heart block
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Trakya University Coordinator of this site? Confirm its status | Edirne | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.